LH-RHアナログ徐放製剤における注射部位反応の検討

Abstract

酢酸ゴセレリン(ZLA)あるいは酢酸リュープロレリン(LSR)を2回以上投与した前立腺癌82例(59～87歳)を対象として, 注射部位反応の発現の有無, 状況について検討した。注射部位反応はZLA群34例中3例(8.8%), LSR群48例中7例(14.6%)に認め, 両群間で有意差はなかった。硬結はZLA群2例とLSR群6例に認めた。LH-RHアナログの3ヵ月製剤は, 頻度は低いが注射部位反応として硬結, 潰瘍などの合併症が起こりうることを念頭に置くべきである。

Luteinizing hormone-releasing hormone agonist (LH-RH analogue) therapy, is one of the most widely used hormonal therapies. Recently, subcutaneous injection of a new long acting 3-month LHRH analogue depot has been developed. We investigated the adverse events induced by injection of an LH-RH analogue in 82 patients (median age was 75 year old, 59-87) using our questionnaire. Forty-eight and 34 cases had been administered leuprorelin acetate (LSR) and goserelin acetate (ZLA). The presentation rate of skin reaction was 8.8% (3/34) in the ZLA group and 14.6% (7/48) in the LSR group. There was no significant difference in rate of skin reaction between the LSR and ZLA group (p = 0.5113). Eight patients had induration (6 in LSR 2 in ZLA). We also present a case of subcutaneous granuloma formation at the injection site after using the three-month type preparation of leuprorelin acetate. We should be aware of the risk of skin reactions at the injection site and monitor carefully when using an LH-RH analogue.